Actionable news
0
All posts from Actionable news
Actionable news in KTOV: KITOV PHARAMCEUTICALS HOLDINGS Ltd. AMERICAN DEPOSITARY SHARES,

Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards

TEL-AVIV, Israel, May 10, 2016 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that KIT-302 has successfully completed its pharmacokinetic (PK) bioequivalence (BE) study and successfully met the U.S. Food and Drug Administration's (FDA) standards for establishing bioequivalence to the reference drugs.

The study compared the PK of Kitov's drug product of KIT-302 which is a fixed dose combination consisting of celecoxib (200 mg), indicated for osteoarthritis pain, and amlodipine (10 mg), indicated for high blood pressure, to off-the-shelf branded 200 mg celecoxib capsules and 10 mg amlodipine tablets. These evaluations were conducted under both fed and fasted conditions. The results demonstrated that for both the Cmax (the maximum blood level achieved) and Area Under the Curve (the area under the concentration time curve for drug levels), the 90% confidence intervals for both the amlodipine and celecoxib components of KIT-302 were documented to be between 80% and 125% of the values obtained with the off-the-shelf drugs. These results mean Kitov has fulfilled the FDA standard for demonstrating BE under both fed and fasted conditions.

"We are pleased to complete our pharmacokinetic BE study on schedule this quarter. These results bring us one step closer towards submitting our New Drug Application to the FDA for KIT-302 at the end of this year and the anticipated marketing approval in 2017," stated Dr. J. Paul Waymack, Chairman of Kitov's Board and Chief Medical...


More